论文部分内容阅读
目的观察尼莫通 (Nimotop)治疗新生儿缺氧缺血性脑病 (HIE)的疗效及预后。方法 74例 HIE患儿随机分为两组。治疗组 41例 ,对照组 3 3例 ,两组均给予常规治疗 ,治疗组加用尼莫通 3～ 5 mg/ (kg· d) ,口服 ,疗程平均 (16.8± 2 .7)天。观察两组患儿在治疗前后新生儿神经行为评分 (NBNA) ,并随访 12个月。结果治疗组 NBNA≥ 3 5分 :第 7、14天分别为 2 3 (5 6.1% )、3 4(82 .9% )例 ,对照组为10 (3 0 .3 % )、2 0 (60 .6% )例 ,两组比较有显著性差异 (P<0 .0 5 )。随访 12个月 ,神经系统后遗症发生率治疗组 4.9% ,显著低于对照组2 1.2 % (P<0 .0 5 ) ,治疗组发育商明显高于对照组 (P<0 .0 5 )。结论尼莫通治疗新生儿缺氧缺血性脑病 ,能减少后遗症的发生 ,改善其预后
Objective To observe the efficacy and prognosis of Nimotop in neonates with hypoxic-ischemic encephalopathy (HIE). Methods 74 children with HIE were randomly divided into two groups. 41 cases in the treatment group and 33 cases in the control group. Both groups were given routine treatment. The treatment group was treated with nimoton 3 ~ 5 mg / (kg · d) orally for a mean of (16.8 ± 2.7) days. The neonatal neurobehavioral score (NBNA) of both groups before and after treatment were observed and followed up for 12 months. Results In the treatment group, the NBNA≥3 5 points were 23 (6.11%) and 34 (82.9%) on the 7th and 14th days, respectively, while the control group was 10 (30.3%) and 20 .6%) cases, there was a significant difference between the two groups (P <0. 05). After 12 months of follow-up, the incidence of neurological sequelae in treatment group was 4.9%, which was significantly lower than that in control group (1.2%, P <0.05). The developmental quotient of treatment group was significantly higher than that of control group (P <0.05). Conclusion Nimotong treatment of neonatal hypoxic-ischemic encephalopathy, can reduce the incidence of sequelae and improve their prognosis